4ZB.F Duality Biotherapeutics, Inc.

Healthcare Biotechnology Frankfurt Exchange
12.00 EUR
Close of Nov 11, 2026
11.80 39.80
Market cap
EUR 1.09B
P/E
-
P/B
5.51x
ROE
-106.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4ZB.F undervalued?

Graham number

The Graham number of Duality Biotherapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Duality Biotherapeutics, Inc. fundamental analysis

No fundamental analysis for Duality Biotherapeutics, Inc. yet.

Duality Biotherapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, eso…

Full company profile